# Peluntamig

Source: https://onco.cc/drugs/peluntamig/  
OnCo record `peluntamig` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.

## Summary

Peluntamig (PT217) is a bispecific antibody developed by Phanes Therapeutics. Its targets are CD47 and DLL3. ClinicalTrials.gov describes the intervention as: A bispecific antibody (bsAb) against DLL3 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT05652686, plans to enrol 203 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Peluntamig (PT217)
- Tags: pipeline; ctgov-ingest
- Code: PT217
- Modality: bispecific antibody
- Mechanism: Bispecific antibody directed at CD47 and DLL3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of Peluntamig: https://clinicaltrials.gov/search?intr=PT217

## Connected records

- cancers: [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [CD47](https://onco.cc/targets/cd47/), [DLL3](https://onco.cc/targets/dll3/)
- companies: [Phanes Therapeutics](https://onco.cc/companies/phanes-therapeutics/)
- trials: [A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)](https://onco.cc/trials/nct05652686/)
- drugs: [Obrixtamig](https://onco.cc/drugs/obrixtamig/)

---
JSON: https://onco.cc/api/v1/entities/peluntamig.json